2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. DYRK

DYRK

Dual specificity tyrosine phosphorylation regulated kinase; Dual specificity tyrosine regulated kinase

DYRK

Related Products

PDF 0.48 MB

DYRKs (dual-specificity tyrosine-regulated kinases; dual-specificity tyrosine phosphorylation-regulated kinases) comprise a family of protein kinases within the CMGC group of the eukaryotic kinome. DYRKs contain five members in humans that are clustered into two classes based on their phylogenetic relationships: class I DYRKs, DYRK1A and DYRK1B and class II DYRKs, DYRK2, DYRK3, and DYRK4.

DYRK kinases are “dual specificity” kinases, as they can phosphorylate both tyrosine (Y) and serine/threonine (S/T) residues, although Y-phosphorylation is limited to their autophosphorylation activity. DYRK kinases phosphorylate a broad set of substrates that are involved in a wide range of cellular processes, and they are thought to fulfill essential biological functions both during development and in maintaining homeostasis during the adult life. Consequently, the aberrant regulation or expression of DYRK kinases has been associated with several human pathologies, including cancer.

DYRK Isoform Specific Products:

DYRK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-RS04099
    Dyrk2 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Dyrk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dyrk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Dyrk2 Mouse Pre-designed siRNA Set A
    Dyrk2 Mouse Pre-designed siRNA Set A
  • HY-139830
    Dyrk1A-IN-1
    		Inhibitor
    Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC50 = 119 nM) and the aggregation of tau and α-syn oligomers.
    Dyrk1A-IN-1
  • HY-161014
    DYRK2-IN-1
    		Inhibitor
    DYRK2-IN-1 (Compd 54) is an orally bioavailable DYRK2 inhibitor, with an IC50 of 14 nM. DYRK2-IN-1 (Compd 54) can be used in the study of prostate cancer.
    DYRK2-IN-1
  • HY-162750
    ZJCK-6-46
    		Inhibitor
    ZJCK-6-46 (32) is a potential and orally activeDYRK1A inhibitor (IC50 = 0.68 nM) with high BBB permeability (CNS+). ZJCK-6-46 (32) reduces tau phosphorylation. ZJCK-6-46 (32) ameliorates cognitive dysfunction by obviously reducing the expression of phosphorylated tau and neuronal loss in vivo.
    ZJCK-6-46
  • HY-RS04098
    DYRK2 Human Pre-designed siRNA Set A
    		Inhibitor

    DYRK2 Human Pre-designed siRNA Set A contains three designed siRNAs for DYRK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    DYRK2 Human Pre-designed siRNA Set A
    DYRK2 Human Pre-designed siRNA Set A
  • HY-P3812
    Woodtide
    Woodtide is a substrate for the DYRK (DYRK) family of kinases whose sequence is based on that around the DYRK phosphorylation site in FKHR.
    Woodtide
  • HY-144696
    Dyrk1A/α-synuclein-IN-2
    		Inhibitor
    Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual Dyrk1A and α-synuclein aggregation inhibitor with an IC50 of 7.8 µM for α-synuclein. Dyrk1A/α-synuclein-IN-2 has high predictive CNS penetration and neuroprotective effect.
    Dyrk1A/α-synuclein-IN-2
  • HY-163514
    hAChE-IN-8
    		Inhibitor
    hAChE-IN-8 (Compound S-12) is a orally effective and selective inhibitor of hAChE (IC50=0.486 μM). hAChE-IN-8 also inhibits BACE-1 (IC50=0.542 μM), and does not inhibit Dyrk1A (IC50>10 μM). hAChE-IN-8 can reduce Aβ aggregation, has good blood-brain barrier penetration. hAChE-IN-8 is mainly used in Alzheimer's disease research.
    hAChE-IN-8
  • HY-N2892
    Aristolactam A IIIa
    		Inhibitor
    Aristolactam A IIIa (Sch 546909) is an aristolactam-type alkaloid that can be isolated from Glycosmis chlorosperma. Aristolactam A IIIa is a DYRK1A Inhibitor. Aristolactam A IIIa inhibits platelet aggregation induced by arachidonic acid (AA), collagen and platelet-activating factor (PAF). Aristolactam A IIIa has strong cytotoxic effect on HeLa cells.
    Aristolactam A IIIa
  • HY-144617
    JH-XIV-68-3
    		Inhibitor
    JH-XIV-68-3 is a selective macrocyclic inhibitor of DYRK1A/B. JH-XIV-68-3 displays selectivity for DYRK1A and close family member DYRK1B in biochemical and cellular assays. JH-XIV-68-3 demonstrates antitumor efficacy in head and neck squamous cell carcinoma (HNSCC) cell lines.
    JH-XIV-68-3
  • HY-128759
    DYRKs-IN-2
    		Inhibitor
    DYRKs-IN-2 (Example 132) is a potent DYRKs inhibitor with IC50s of 30.6 nM and 12.8 nM for DYRK1B and DYRK1A, respectively. DYRKs-IN-2 has antitumor activity.
    DYRKs-IN-2
  • HY-129449
    AnnH31
    		Inhibitor 99.91%
    AnnH31 is a Dyrk1A inhibitor (IC50: 81 nM). AnnH31 also inhibits MAO-A with an IC50 of 3.2 μM. AnnH31 inhibits cell viability of HeLa, PC12 and SH-SY5Y cells.
    AnnH31
  • HY-RS04100
    Dyrk2 Rat Pre-designed siRNA Set A
    		Inhibitor

    Dyrk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dyrk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Dyrk2 Rat Pre-designed siRNA Set A
    Dyrk2 Rat Pre-designed siRNA Set A
  • HY-159496
    Dyrk1A-IN-10
    		Inhibitor
    Dyrk1A-IN-10 (compound B4) is a DYRK1A inhibitor with antidiabetic activity. Dyrk1A-IN-10 can promote pancreatic β-cell proliferation, increase insulin secretion, and lower blood sugar.
    Dyrk1A-IN-10
  • HY-173615
    KTD-092
    		Inhibitor
    KTD-092 is a hit for DYRK1A inhibition, with an IC50 of 22 nM for human DYRK1A. KTD-092 can be used in the research for Down syndrome (DS), Alzheimer's disease (AD), autism spectrum disorder (ASD), diabetes and other neurodegenerative diseases.
    KTD-092
  • HY-158212
    Dyrk1A-IN-8
    		Inhibitor
    Dyrk1A-IN-8 (compound 4C) is a potent inhibitor of Dyrk1A , with the IC50 of 209 nM. Dyrk1A-IN-8 plays an important role in neurodegenerative diseases.
    Dyrk1A-IN-8
  • HY-146586
    Haspin-IN-1
    		Inhibitor
    Haspin-IN-1 (compound 2a) is a haspin inhibitor with an IC50 of 119 nM. Haspin-IN-1 also inbibits CLK1 and DYRK1A with IC50s of 221 nM and 916.3 nM, respectively.
    Haspin-IN-1
  • HY-RS04103
    Dyrk3 Rat Pre-designed siRNA Set A
    		Inhibitor

    Dyrk3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dyrk3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Dyrk3 Rat Pre-designed siRNA Set A
    Dyrk3 Rat Pre-designed siRNA Set A
  • HY-142295A
    GNF2133 hydrochloride
    		Inhibitor
    GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes.
    GNF2133 hydrochloride
  • HY-147760
    Dyrk1A-IN-2
    		Inhibitor
    Dyrk1A-IN-2 (Compound 63) is a DYRK1A inhibitor with an EC50 of 37 nM. Dyrk1A-IN-2 exhibits highly potent human β-cell replication-promoting activity and low cytotoxicity.
    Dyrk1A-IN-2
Cat. No. Product Name / Synonyms Application Reactivity
DYRK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.